Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Given Consensus Rating of "Hold" by Brokerages

Key Points

• Inovio Pharmaceuticals has received a consensus rating of "Hold" from analysts, with one sell, three hold, and three buy recommendations.
• The average 1-year price target for the stock is $8.80, while it currently trades around $2.46.
• Recent earnings showed an EPS of ($0.61), exceeding analysts' expectations of ($0.63), with forecasts of a further -4.23 EPS for the current year.

Inovio Pharmaceuticals, Inc. (NASDAQ:INO - Get Free Report) has been given a consensus rating of "Hold" by the seven analysts that are covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, three have issued a hold recommendation and three have assigned a buy recommendation to the company. The average 1-year price objective among analysts that have covered the stock in the last year is $8.80.

Several equities analysts recently issued reports on the stock. Piper Sandler assumed coverage on shares of Inovio Pharmaceuticals in a report on Wednesday, July 9th. They set an "overweight" rating and a $5.00 price target for the company. Wall Street Zen cut shares of Inovio Pharmaceuticals from a "hold" rating to a "sell" rating in a research note on Saturday, August 16th. Zacks Research downgraded Inovio Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, September 3rd. Weiss Ratings reiterated a "sell (e+)" rating on shares of Inovio Pharmaceuticals in a research report on Wednesday, October 8th. Finally, HC Wainwright reiterated a "neutral" rating and issued a $3.00 price objective on shares of Inovio Pharmaceuticals in a research report on Thursday, August 14th.

Inovio Pharmaceuticals Stock Performance

NASDAQ:INO opened at $2.46 on Friday. The company has a 50-day moving average of $2.30 and a 200-day moving average of $1.96. The company has a market capitalization of $130.72 million, a price-to-earnings ratio of -0.94 and a beta of 1.65. Inovio Pharmaceuticals has a 52 week low of $1.30 and a 52 week high of $5.83.

Inovio Pharmaceuticals (NASDAQ:INO - Get Free Report) last announced its quarterly earnings results on Tuesday, August 12th. The biopharmaceutical company reported ($0.61) EPS for the quarter, topping analysts' consensus estimates of ($0.63) by $0.02. Sell-side analysts forecast that Inovio Pharmaceuticals will post -4.23 EPS for the current year.

Hedge Funds Weigh In On Inovio Pharmaceuticals

Institutional investors have recently modified their holdings of the stock. Nomura Holdings Inc. bought a new position in shares of Inovio Pharmaceuticals in the first quarter worth about $28,000. Catalyst Funds Management Pty Ltd bought a new position in Inovio Pharmaceuticals in the 2nd quarter worth approximately $35,000. Freedom Investment Management Inc. bought a new position in Inovio Pharmaceuticals in the 1st quarter worth approximately $31,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in Inovio Pharmaceuticals by 39.6% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 20,781 shares of the biopharmaceutical company's stock worth $34,000 after purchasing an additional 5,894 shares during the last quarter. Finally, Jane Street Group LLC raised its position in shares of Inovio Pharmaceuticals by 221.2% during the second quarter. Jane Street Group LLC now owns 39,683 shares of the biopharmaceutical company's stock worth $81,000 after acquiring an additional 27,329 shares during the last quarter. 26.79% of the stock is owned by institutional investors.

Inovio Pharmaceuticals Company Profile

Inovio Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.